Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 138
- Registration Number
- NCT05104567
- Locations
- 🇺🇸
Seattle Cancer Care Alliance Site Number : 8400009, Seattle, Washington, United States
🇳🇱Investigational Site Number : 5280001, Amsterdam, Netherlands
🇮🇹Investigational Site Number : 3800003, Milano, Italy
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 830
- Registration Number
- NCT05067283
- Locations
- 🇺🇸
Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States
🇺🇸START Midwest ( Site 0267), Grand Rapids, Michigan, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
- Conditions
- Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage IV Sinonasal Cancer AJCC v8Metastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Nasopharyngeal Squamous Cell CarcinomaClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Metastatic Lip and Oral Cavity CarcinomaMetastatic Nasal Cavity Squamous Cell CarcinomaStage IV Hypopharyngeal Carcinoma AJCC v8Stage IV Laryngeal Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 430
- Registration Number
- NCT05063552
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Epic Care-Dublin, Dublin, California, United States
🇺🇸Epic Care Partners in Cancer Care, Emeryville, California, United States
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 59
- Registration Number
- NCT05061420
- Locations
- 🇺🇸
City of Hope- Site Number : 8400007, Duarte, California, United States
🇺🇸University of Colorado- Site Number : 8400004, Aurora, Colorado, United States
🇺🇸University of Michigan- Site Number : 8400008, Ann Arbor, Michigan, United States
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05040568
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05039177
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 195
- Registration Number
- NCT05012618
- Locations
- 🇺🇸
University of California - Davis, Davis, California, United States
🇺🇸Beth Israel Deaconess, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 103
- Registration Number
- NCT05004350
- Locations
- 🇨🇳
Fujian Medical University - Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 81
- Registration Number
- NCT04966481
- Locations
- 🇺🇸
Saint Luke's Hospital, Kansas City, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 550
- Registration Number
- NCT04956640
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, Rhône-Alpes, France
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇦🇺Peninsula and Southeast Oncology, Frankston, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.